2024

1. Prediction of individual lifetime cardiovascular risk and potential treatment benefit: Development and recalibration of the LIFE-CVD2 model to four European risk regions

   European Journal of Preventive Cardiology, Vol. 31, Núm. 14, pp. 1690-1699

2. Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study

   British Journal of Dermatology, Vol. 191, Núm. 3, pp. 419-427